INDIANAPOLIS,?June 3, 2020?/PRNewswire/ --?Eli Lilly and Company?(NYSE: LLY) will present new data for Olumiant^??(baricitinib) at the virtual?European Congress of Rheumatology?(EULAR?2020) taking place?June 3-6, 2020. Highlights from Olumiant data being presented at the virtual meeting include new long-term data in patients living with rheumatoid arthritis (RA) as well as data from an investigational trial in patients with systemic lupus erythematosus (SLE).

"We're pleased to be participating in this year's virtual?EULAR?meeting sharing new safety and efficacy data in people living with RA who have been treated with Olumiant," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at?Lilly. "At?Lilly, our focus on patient needs doesn't stop when we launch a product. We're committed to continuously evaluating potential treatment options for patients living with rheumatic conditions."

At this year's meeting,?Lilly?will share results from a long-term study that evaluated the efficacy of Olumiant in patients with moderate to severe RA during three years of treatment. The study measured the achievement of clinically-relevant outcomes, including low disease activity (LDA) as measured by the simplified disease activity index (SDAI =11), in DMARD-na?ve patients and patients with an inadequate response to methotrexate (MTX-IR) from treatment initiation to three years. Patients in this study were treated with Olumiant 4-mg once daily, an approved dose outside of?North America.

The study found that among patients with an inadequate response to MTX, 52% of patients initially treated with Olumiant (+MTX) were in a state of SDAI LDA at week 24 and this rate was maintained through week 148.

Lilly?will also share an updated integrated safety analysis of Olumiant in the treatment of RA using data from 3,770 patients who were treated with the medicine for up to 8.4 years. The study found that Olumiant's safety profile remains consistent with what has been previously reported, with no increase in the rates of safety topics of interest, including serious infections, herpes zoster, major adverse cardiovascular events, deep-vein thrombosis and/or pulmonary embolism, non-melanoma skin cancer (NMSC), and non-NMSC malignancies. No new safety signals were identified.

"The results from?Lilly's integrated safety analysis help to further characterize the long-term safety of Olumiant as a treatment option in patients with RA," said?Kevin Winthrop, professor of medicine at the?Oregon Health and Sciences University?and author of the Olumiant safety abstract.

In addition,?Lilly?will present analyses from an investigational trial evaluating baricitinib in patients with SLE at?EULAR. Data from its Phase 2 randomized, placebo-controlled, double-blind JAHH study will be highlighted, which observed whether or not SLE patients experienced changes in their serum cytokine levels when being treated with the 4-mg dose of baricitinib.

For more information about the?Lilly?data being presented at this year's virtual?EULAR?congress, please visit?https://www.congress.eular.org/scientific_programme.cfm.

Indication and Usage for OLUMIANT (baricitinib) tablets (in?the?United States) for RA patients

OLUMIANT^??(baricitinib) 2-mg is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.?Limitation of Use: Use of OLUMIANT in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

IMPORTANT SAFETY INFORMATION FOR OLUMIANT (baricitinib) TABLETS?

WARNING: SERIOUS INFECTIONS, MALIGNANCY, AND THROMBOSIS SERIOUS INFECTIONS:?Patients treated with Olumiant are at risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt Olumiant until the infection is controlled. Reported infections include:

• Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease. Test patients for latent TB before initiating Olumiant and during therapy. Treatment for latent infection should be considered prior to Olumiant use.
• Invasive fungal infections, including candidiasis and pneumocystosis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
• Bacterial, viral, and other infections due to opportunistic pathogens.

Carefully consider the risks and benefits of Olumiant prior to initiating therapy in patients with chronic or recurrent infection.

Closely monitor patients for the development of signs and symptoms of infection during and after treatment with Olumiant including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

MALIGNANCIES:?Lymphoma and other malignancies have been observed in patients treated with Olumiant.

THROMBOSIS:?Thrombosis, including deep venous thrombosis (DVT) and pulmonary embolism (PE), has been observed at an increased incidence in patients treated with Olumiant compared to placebo. In addition, there were cases of arterial thrombosis. Many of these adverse events were serious and some resulted in death. Patients with symptoms of thrombosis should be promptly evaluated.

WARNINGS AND PRECAUTIONS

SERIOUS INFECTIONS:?The most common serious infections reported with Olumiant included?pneumonia, herpes zoster and urinary tract infection. Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus and BK virus were reported with Olumiant. Some patients have presented with disseminated rather than local disease and were often taking concomitant immunosuppressants such as methotrexate or corticosteroids. Avoid Olumiant in patients with an active, serious infection, including localized infections. Consider the risks and benefits of treatment prior to initiating Olumiant in patients:

• with chronic or recurrent infection
• who have been exposed to TB
• with a history of a serious or an opportunistic infection
• who have resided or traveled in areas of endemic tuberculosis or endemic mycoses; or
• with underlying conditions that may predispose them to infection.

Closely monitor patients for infections during and after Olumiant treatment. Interrupt Olumiant if a patient develops a serious infection, an opportunistic infection, or sepsis. Do not resume Olumiant?until the infection is controlled.

Tuberculosis???Before initiating Olumiant?evaluate and test patients for latent or active infection and treat patients with latent TB with standard antimycobacterial therapy. Olumiant should not be given to patients with active TB. Consider anti-TB therapy prior to initiating Olumiant in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection. Monitor patients for TB during Olumiant treatment.

Viral Reactivation???Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), were reported in clinical studies with Olumiant. If a patient develops herpes zoster, interrupt Olumiant treatment until the episode resolves.

The impact of Olumiant on chronic viral hepatitis reactivation is unknown. Screen for viral hepatitis in accordance with clinical guidelines before initiating Olumiant.

MALIGNANCY AND LYMPHOPROLIFERATIVE DISORDERS:?Malignancies were observed in Olumiant clinical studies. Consider the risks and benefits of Olumiant prior to initiating therapy in patients with a known malignancy other than a successfully treated non-melanoma skin cancer (NMSC) or when considering continuing Olumiant in patients who develop a malignancy. NMSCs were reported in patients treated with Olumiant. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.

THROMBOSIS:?Thrombosis, including DVT and PE, has been observed at an increased incidence in Olumiant-treated patients compared to placebo. In addition, arterial thrombosis events in the extremities have been reported in clinical studies with Olumiant. Many of these adverse events were serious and some resulted in death. There was no clear relationship between platelet count elevations and thrombotic events. Use Olumiant?with caution in patients who may be at increased risk of thrombosis. If clinical features of DVT/PE or arterial thrombosis occur, evaluate patients promptly and treat appropriately.

GASTROINTESTINAL PERFORATIONS:?Gastrointestinal perforations have been reported in Olumiant clinical studies, although the role of JAK inhibition in these events is not known. Use Olumiant?with caution in patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis). Promptly evaluate patients who present with new onset abdominal symptoms for early identification of gastrointestinal perforation.

LABORATORY ABNORMALITIES:

Neutropenia???Olumiant treatment was associated with an increased incidence of neutropenia (absolute neutrophil count [ANC] <1000?cells/mm³) compared to placebo. Avoid initiation or interrupt Olumiant treatment in patients with an ANC <1000?cells/mm³. Evaluate at baseline and thereafter according to routine patient management.

Lymphopenia???Absolute lymphocyte count (ALC) <500?cells/mm³?were reported in Olumiant clinical trials. Lymphocyte counts less than the lower limit of normal were associated with infection in patients treated with Olumiant, but not placebo. Avoid initiation or interrupt Olumiant treatment in patients with an ALC <500?cells/mm³. Evaluate at baseline and thereafter according to routine patient management.

Anemia???Decreases in hemoglobin levels to <8?g/dL were reported in Olumiant clinical trials. Avoid initiation or interrupt Olumiant treatment in patients with hemoglobin <8?g/dL. Evaluate at baseline and thereafter according to routine patient management.

Liver Enzyme Elevations???Olumiant treatment was associated with increased incidence of liver enzyme elevation compared to placebo. Increases to =5x and =10x upper limit of normal were observed for both ALT and AST in patients in Olumiant clinical trials.

Evaluate at baseline and thereafter according to routine patient management. Promptly investigate the cause of liver enzyme elevation to identify potential cases of drug-induced liver injury. If increases in ALT or AST are observed and drug-induced liver injury is suspected, interrupt Olumiant until this diagnosis is excluded.

Lipid Elevations???Treatment with Olumiant was associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol. Assess lipid parameters approximately 12?weeks following Olumiant initiation. Manage patients according to clinical guidelines for the management of hyperlipidemia.

VACCINATIONS:??Avoid use of live vaccines with Olumiant. Update immunizations in agreement with current immunization guidelines prior to initiating Olumiant therapy.

ADVERSE REACTIONS Adverse reactions (=1%) include: upper respiratory tract infections (16.3%, 14.7%, 11.7%), nausea (2.7%, 2.8%, 1.6%), herpes simplex (0.8%, 1.8%, 0.7%) and herpes zoster (1.0%, 1.4%, 0.4%) for Olumiant 2 mg, baricitinib 4 mg, and placebo, respectively.

USE IN SPECIFIC POPULATIONS

PREGNANCY AND LACTATION:?No information is available to support the use of Olumiant in pregnancy or lactation. Advise women not to breastfeed during treatment with Olumiant.

HEPATIC AND RENAL IMPAIRMENT:?Olumiant is not recommended in patients with severe hepatic impairment or in patients with severe renal impairment.

Please click to access full?Prescribing Information,?including Boxed Warning about Serious infections, Malignancies, and Thrombosis, and?Medication Guide.

BA HCP ISI 11OCT2019

About OLUMIANT^? OLUMIANT is a once-daily, oral JAK inhibitor approved in the?U.S.?for the treatment of adults with moderately- to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF inhibitor therapies, and approved outside of the?U.S.?for patients with moderately- to severely active rheumatoid arthritis who have had an inadequate response to one or more DMARDs.¹?There are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2. JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases.²?OLUMIANT has greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3; however, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.¹?OLUMIANT is approved in more than 60 countries. Olumiant is developed by?Lilly?under license from Incyte Corporation.

About?Eli?Lilly?and Company Lilly?is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe,?Lilly?employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about?Lilly, please visit us at?lilly.com?and?lilly.com/newsroom. P-LLY

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about OLUMIANT (baricitinib) as a treatment for patients with rheumatoid arthritis and a potential treatment for patients with systemic lupus erythematosus and reflects?Lilly's and?Incyte's?current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that OLUMIANT will receive additional regulatory approvals, or that it will be commercially successful. For further discussion of these and other risks and uncertainties, see?Lilly's and?Incyte's?most recent respective Form 10-K and Form 10-Q filings with the?United States Securities and Exchange Commission. Except as required by law,?Lilly?and?Incyte?undertake no duty to update forward-looking statements to reflect events after the date of this release.

¹?Olumiant Prescribing Information, 2019. ²?Walker JG and Smith MD. J Rheumatol. 2005;32;1650-1653.